FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      amgnndaq

      ·

      FDA Warns Of Fatal Liver Risks Linked To Amgen Tavneos Use

      The U.S. Food and Drug Administration (FDA) has warned patients and healthcare providers about serious and sometimes fatal liver injuries tied to Amgen Inc.’s (NASDAQ:AMGN) Tavneos (avacopan), citing postmarketing data that point to new safety concerns beyond those identified in clinical trials.

      Tavneos, approved in October 2021, is used in combination with glucocorticoids and other therapies to treat adults with severe active ANCA-associated vasculitis, a rare autoimmune condition affecting small- to medium-sized blood vessels.

      New Safety Signal Emerges For Tavneos

      The agency said cases of drug-induced liver injury (DILI), including a rare but severe condition known as vanishing bile duct syndrome (VBDS), have been reported in patients treated with Tavneos.

      VBDS involves progressive destruction of bile ducts, potentially leading to impaired bile flow and permanent ...

      Full story available on Benzinga.com


      Source: Benzinga
      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud